Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple endocrine neoplasia type 2: 2007 update.

Friedhelm Raue1, Karin Frank-Raue

  • 1friedhelm.raue@raue.endokrinologie.de

Hormone Research
|February 7, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2025
Same author

Epidemiology, Clinical Presentation, and Diagnosis of Medullary Thyroid Carcinoma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2025
Same author

Medullary Thyroid Carcinoma: Imaging.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2025
Same author

Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2025
Same author

Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2025
Same author

The Long-Term Cure of Patients With Hereditary Medullary Thyroid Carcinoma: 40 Years of Follow-Up in a Single Center.

Deutsches Arzteblatt international·2024
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Multiple endocrine neoplasia type 2 (MEN-2) is a genetic disorder caused by RET gene mutations. Genetic testing identifies carriers, enabling early cancer prevention and treatment strategies.

Area of Science:

  • Endocrinology
  • Genetics
  • Oncology

Background:

  • Multiple endocrine neoplasia type 2 (MEN-2) is an autosomal dominant tumor syndrome.
  • Caused by germline-activating mutations in the RET proto-oncogene.
  • Characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism (MEN-2A), or MTC, pheochromocytoma, and mucosal neuroma (MEN-2B).

Purpose of the Study:

  • To summarize the clinical characteristics and genetic basis of MEN-2.
  • To highlight the importance of genetic testing in identifying mutation carriers.
  • To discuss the implications for cancer prevention and treatment strategies.

Main Methods:

  • Review of existing literature on MEN-2.
  • Analysis of genotype-phenotype correlations.

Related Experiment Videos

  • Discussion of genetic testing protocols and risk stratification.

    • Main Results:

    • Genetic testing detects nearly 100% of mutation carriers.
    • A strong genotype-phenotype correlation exists for different MEN-2 variants.
    • Risk-level classification based on genotype guides prophylactic thyroidectomy timing and surgical extent.

    Conclusions:

    • MEN-2 serves as a model for early cancer prevention and cure.
    • Mutation-based diagnosis enables stratified carrier management.
    • Genetic insights facilitate personalized treatment approaches for MEN-2 patients.